Phase I b/ II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan ( JK1201I ) as second‐line monotherapy for patients with small‐cell lung cancer
Cancer Medicine · 2024
DOI: 10.1002/cam4.70059 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Medicine, 2024. Verfasst von Jieran Long und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Beijing University Cancer Hospital, Beijing, China. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Irinotecan, Polyethylene Glycols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To evaluate the safety, tolerability, and preliminary efficacy of multiple doses of pegylated irinotecan (JK1201I) as a second‐line monotherapy for treating small‐cell lung cancer (SCLC) patients.
Methods
According to the “3 + 3” dose‐escalation principle, patients received intravenous JK1201I at 180 or 220 mg/m 2 once every 3 weeks for four cycles. Progression‐free survival (PFS), overall survival (OS), median progression‐free survival (mPFS), and median overall survival (mOS) were evaluated. The Kaplan–Meier method was used to analyze PFS and overall OS. Brookmeyer and Crowley's method was used for mPFS and mOS.
Results
This study included 29 patients with stage III–IV SCLC (stage IIIa, n = 1; stage IIIb, n = 1; and stage IV, n = 27). Of these, 26 patients were enrolled in the 180 mg/m 2 dose group, and 3 patients were enrolled in the 220 mg/m 2 dose group. No dose‐limiting toxicity (DLT) was noted during the first 28 days of treatment. Grade 3 or higher adverse events were recorded in the 180 mg/m 2 group, including diarrhea (11.5%, 3/26), neutropenia (7.7%, 2/26), and leukopenia (7.7%, 2/26). In the 220 mg/m 2 group, one patient (33.3%, 1/3) experienced neutropenia or leukopenia. In the 180 mg/m 2 group, 38.5% (10/26) of patients achieved an objective response rate (ORR), with a disease control rate (DCR) of 73.1% (19/26). The mPFS and mOS were 3.4 and 12.1 months, respectively. In the 220 mg/m 2 group, one patient had stable disease, and one had progressive disease (PD). The ORR, DCR, mPFS, and mOS were 0% (0/3) and 33.3% (1/3), 2.7 months and 2.7 months, respectively.
Conclusion
JK1201I exhibits promising efficacy and relatively low toxicities as a second‐line monotherapy for SCLC, warranting further large‐scale clinical studies to evaluate its efficacy in greater detail.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology, Beijing University Cancer Hospital, Beijing, China.
- Department of Clinical Medicine and Pharmacology, JenKemTechnology Co., Ltd. (Tian Jin), Tianjin, China.
- Thoracic Medicine Department, Hunan Cancer Hospital, Changsha, Hunan, China.
- Medicine Oncology Department, Weifang People's Hospital, Weifang, Shandong, China.
- Internal Medicine Oncology Ward, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
- Department of Respiratory Medicine, Henan Cancer Hospital, Zhengzhou, Henan, China.
Zitieren
APA
Long, J., Li, X., Wu, L., Yu, G., Zang, A., Zhao, Y., Shi, J., Nie, L., Zhao, X., & Fang, J. (2024). Phase I b/ II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan ( JK1201I ) as second‐line monotherapy for patients with small‐cell lung cancer. Cancer Medicine. https://doi.org/10.1002/cam4.70059
Vancouver
Long J, Li X, Wu L, Yu G, Zang A, Zhao Y, et al. Phase I b/ II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan ( JK1201I ) as second‐line monotherapy for patients with small‐cell lung cancer. Cancer Medicine. 2024. doi:10.1002/cam4.70059
BibTeX
@article{Long2024,
author = {Long, Jieran and Li, Xuefei and Wu, Lin and Yu, Guohua and Zang, Aimin and Zhao, Yanqiu and Shi, Jinsheng and Nie, Ligong and Zhao, Xuan and Fang, Jian},
title = {Phase I b/ II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan ( JK1201I ) as second‐line monotherapy for patients with small‐cell lung cancer},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70059}
}
EUVIMED